Back to Search
Start Over
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
- Source :
-
Circulation [Circulation] 2013 Aug 13; Vol. 128 (7), pp. 721-8. Date of Electronic Publication: 2013 Jul 16. - Publication Year :
- 2013
-
Abstract
- Background: The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear. We assessed concomitant ASA use and its association with clinical outcomes among AF patients treated with OAC.<br />Methods and Results: The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry enrolled 10 126 AF patients from 176 US practices from June 2010 through August 2011. The study population was limited to those on OAC (n=7347). Hierarchical multivariable logistic regression models were used to assess factors associated with concomitant ASA therapy. Primary outcomes were 6-month bleeding, hospitalization, ischemic events, and mortality. Overall, 35% of AF patients (n=2543) on OAC also received ASA (OAC+ASA). Patients receiving OAC+ASA were more likely to be male (66% versus 53%; P<0.0001) and had more comorbid illness than those on OAC alone. More than one third of patients (39%) receiving OAC+ASA did not have a history of atherosclerotic disease, yet 17% had elevated Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) bleeding risk scores (≥5). Major bleeding (adjusted hazard ratio, 1.53; 95% confidence interval, 1.20-1.96) and bleeding hospitalizations (adjusted hazard ratio, 1.52; 95% confidence interval, 1.17-1.97) were significantly higher in those on OAC+ASA compared with those on OAC alone. Rates of ischemic events were low.<br />Conclusions: Patients with AF receiving OAC are often treated with concomitant ASA, even when they do not have cardiovascular disease. Use of OAC+ASA was associated with significantly increased risk for bleeding, emphasizing the need to carefully determine if and when the benefits of concomitant ASA outweigh the risks in AF patients already on OAC.<br />Clinical Trial Registration: URL: http://www.clinicaltrials.gov. UNIQUE IDENTIFIER: NCT01165710.
- Subjects :
- Aged
Aged, 80 and over
Anticoagulants administration & dosage
Anticoagulants adverse effects
Aspirin administration & dosage
Aspirin adverse effects
Atrial Fibrillation mortality
Benzimidazoles administration & dosage
Benzimidazoles adverse effects
Benzimidazoles therapeutic use
Cerebrovascular Disorders epidemiology
Clopidogrel
Comorbidity
Dabigatran
Drug Synergism
Female
Fibrinolytic Agents administration & dosage
Fibrinolytic Agents adverse effects
Fibrinolytic Agents therapeutic use
Follow-Up Studies
Hemorrhage chemically induced
Hospitalization statistics & numerical data
Humans
Hypertrophy, Left Ventricular epidemiology
Logistic Models
Male
Middle Aged
Models, Cardiovascular
Myocardial Ischemia epidemiology
Platelet Aggregation Inhibitors administration & dosage
Platelet Aggregation Inhibitors adverse effects
Prospective Studies
Registries statistics & numerical data
Risk
Ticlopidine administration & dosage
Ticlopidine adverse effects
Ticlopidine analogs & derivatives
Ticlopidine therapeutic use
Treatment Outcome
beta-Alanine administration & dosage
beta-Alanine adverse effects
beta-Alanine analogs & derivatives
beta-Alanine therapeutic use
Anticoagulants therapeutic use
Aspirin therapeutic use
Atrial Fibrillation drug therapy
Platelet Aggregation Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4539
- Volume :
- 128
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Circulation
- Publication Type :
- Academic Journal
- Accession number :
- 23861512
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.113.002927